HyperSHArc: Single-Isocenter Stereotactic Radiosurgery of Multiple Brain Metastases Using Proton, Helium, and Carbon Ion Arc Therapy
Rattachement africain : de, us, ua, it, jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose This work presents a proof-of-concept study of HyperSHArc, spot-scanning hadron arc (SHArc) therapy for single-isocenter stereotactic radiosurgery of multiple brain metastases (MBMs). HyperSHArc plans using proton, helium, and carbon ions were compared with state-of-the-art volumetric modulated photon arc therapy. Methods and Materials Treatment design and optimization procedures were devised using commercial and in-house treatment planning systems. Planning and delivery methods considered dedicated energy, spot, and multiarc selection strategies. Proton, helium, and carbon HyperSHArc plans were generated for patients with MBM exhibiting 3 to 11 intracranial lesions with gross tumor volumes (GTVs) between 0.03 and 19.8 cc, at prescribed doses between 19 and 21Gy in a single-fraction. Planning target volumes (PTVs) considered a 1-mm isotropic margin around the GTV, and robust optimization with 2.5%/1 mm criteria for range and position uncertainty was applied. Photon hyper-arc volumetric modulated arc therapy (HA-VMAT) plans were optimized for the PTVs using the HyperArc® single-isocenter stereotactic radiosurgery platform (Varian, Palo Alto, CA, USA). Results HyperSHArc plans were comparable between particle species, achieving highly conformal target doses and satisfying clinical coverage criteria. Particle arc plans reduced V 2Gy and V 4Gy in the healthy brain compared with HA-VMAT, while intermediate doses (V 8Gy -V 16Gy ) were similar or reduced depending on the number of lesions. Particularly for the case with 11 targets, a considerable reduction in V 12Gy was observed that could be relevant for reducing the risk of treatment-induced radionecrosis. HyperSHArc using carbon ions boosted dose-averaged linear energy transfer inside the target relevant to overcoming radioresistance factors (>100 keV/μm). Conclusions We present the first particle arc therapy strategies for MBM. Results demonstrate that with HyperSHArc, dose conformity comparable or superior to HA-VMAT is achievable while reducing the low-dose bath and increasing mean dose-averaged linear energy transfer in the GTV. Our findings suggest that HyperSHArc using light and heavy ions could be an effective and efficient means of treating MBM. Further development of HyperSHArc optimization and delivery is justified.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- HyperSHArc: Single-Isocenter Stereotactic Radiosurgery of Multiple Brain Metastases Using Proton, Helium, and Carbon Ion Arc Therapy
- Date Crossref
- 01/05/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
GSI Helmholtz Centre for Heavy Ion Research Biophysics pays non établi dans la noticeStructure de recherche
-
Royal Oak Community Coalition pays non établi dans la noticeOrganisation à but non lucratif
-
German Cancer Research Center pays non établi dans la noticeStructure de recherche
-
Heidelberg University National Center for Tumor Diseases (NCT) pays non établi dans la noticeUniversité ou école supérieure
-
Heidelberger Institut für Radioonkologie pays non établi dans la noticeInstitution
-
Deutsches Konsortium für Translationale Krebsforschung pays non établi dans la noticeStructure de recherche
-
Technische Universität Darmstadt pays non établi dans la noticeUniversité ou école supérieure
-
Yukhnovskii Institute for Condensed Matter Physics of the National Academy of Sciences of Ukraine pays non établi dans la noticeStructure de recherche
-
University Hospital Heidelberg pays non établi dans la noticeÉtablissement de santé
-
National Center for Oncological Hadrontherapy pays non établi dans la noticeOrganisation à but non lucratif
-
National Center for Tumor Diseases pays non établi dans la noticeOrganisme public
-
University of Pennsylvania Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
Biophysics — GSI Helmholtz Centre for Heavy Ion Research, Royal Oak Community Coalition et German Cancer Research Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.